News - Anti-virals, Financial


Current filters:


Popular Filters

1 to 25 of 38 results

The price of NOT curing hepatitis C - by Robert Zirkelbach

The price of NOT curing hepatitis C - by Robert Zirkelbach


Over the past few months, there has been increased focus on the price of a new cure for hepatitis C,…

Anti-viralsBiotechnologyFinancialHealthcareHepatitis CHepatitis CLiver transplantsMedicineTradeUSA

Report: US state governments may spend $55 billion on hepatitis C drugs

Report: US state governments may spend $55 billion on hepatitis C drugs


State legislatures in the USA will need to find billions in their budgets to purchase costly new hepatitis…

Anti-viralsExpress ScriptsFinancialGilead SciencesHealthcarePharmaceuticalSovaldiUSA

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program


USA-based Isis Pharmaceuticals has earned yet another $1 million payment from UK pharma giant GlaxoSmithKline,…

Anti-viralsFinancialGlaxoSmithKlineIsis PharmaceuticalsPharmaceuticalResearch

AbbVie opens expanded manufacturing facility in Ireland

AbbVie opens expanded manufacturing facility in Ireland


The chairman and chief of US drugmaker AbbVie, Richard Gonzalez, accompanied by other senior executives,…


Biota Pharma plans restructuring following loss of BARDA contract


USA-based Biota Pharmaceuticals has adopted a plan to restructure the company's operations following…

Anti-viralsBiota PharmaceuticalsBiotechnologyFinanciallaninamivirManagementUSA

Gilead 1st-qtr 2014 sales nearly double, fuelled by Sovaldi, as net income rockets


US antivirals major Gilead Sciences posted first-quarter 2014 results after markets closed yesterday,…

Anti-viralsBiotechnologyFinancialGilead SciencesSovaldi

AbbVie files NDA for oral, interferon-free treatment of hepatitis C


US drugmaker AbbVie has submitted its New Drug Application to the US Food and Drug Administration for…

AbbVieAnti-viralsEnanta PharmaceuticalsFinancialNorth AmericaPharmaceuticalRegulationUSA

NHS England agrees funding for Gilead’s hepatitis C drug Sovaldi


NHS England has approved an £18.7 million ($31.3 million) investment in a new drug for the treatment…

Anti-viralsBiotechnologyFinancialGilead SciencesHealthcareNorthern EuropeSovaldiUK

Pharma Summit: AIDS activists picket to demand South African reform

Pharma Summit: AIDS activists picket to demand South African reform


Delegates at The Economist’s Pharma Summit in London yesterday were greeted by AIDS activists picketing…

Anti-viralsFinancialLegalPharmaceuticalPricingSouth AfricaUK

iCo Therapeutics within reach of ‘holy grail’ cure in the $14 billion HIV market, says Edison


Canadian biotech company iCo Therapeutics’s (iCO: TSX-V) compound AmpB could potentially allow the…

Anti-viralsBiotechnologyCanadaFinancialiCo TherapeuticsResearch

Catalyst-rich period ahead for key trial results from BioLineRx


Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…


Vertex sells Incivo royalty rights to Janssen for $152 million


Loss-making US biotech firm Vertex Pharmaceuticals says that it has sold its product royalty rights relating…

Anti-viralsBiotechnologyFinancialIncivoJanssenJohnson & JohnsonLicensingVertex

New HIV drugs drive Gilead Sciences 3rd-qtr growth

New HIV drugs drive Gilead Sciences 3rd-qtr growth


US biotech Gilead Sciences late yesterday reported strong third-quarter 2013 financial results that were…

Anti-viralsBiotechnologyFinancialGilead Sciences

DC AIDS protesters join push to demand China gives $1 billion to fight global AIDS


The Washington DC, USA based AIDS Healthcare Foundation (AHF) is spearheading a series of US and global…


HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst


While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing a preventative…

Anti-viralsBiotechnologyFinancialHVTN 505PharmaceuticalResearchVaccines

Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program


US biotech firm Gilead Sciences (Nasdaq: GILD) has reported that revenues for the first quarter of 2013…

Anti-viralsBiotechnologyFinancialGilead SciencesledipasvirResearchsofosbuvir

Specialty drug costs account for over 50% of the total cost of care for RA and hepatitis C patients in USA


According to two new studies by Prime Therapeutics, a leading US pharmacy benefit manager, rheumatoid…

Anti-Arthritics/RheumaticsAnti-viralsBiotechnologyFinancialHealthcareNorth AmericaPharmaceutical

Australia to subsidize groundbreaking hepatitis C drugs under PBS


The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

Gilead 4th-qtr sales and earnings beat forecasts, but slammed for "greed" by AHF


USA-based Gilead Sciences (Nasdaq: GILD), the leading maker of HIV/AIDS drugs, yesterday posted financial…

Anti-viralsBiotechnologyFinancialGilead SciencesPricing

News briefs: Novartis drops Ruvise MAA; B-MS settlement; Germany donates to Global Fund


The European Medicines Agency says it has been formally notified by Swiss drug major Novartis (NOVN:…

Anti-viralsBMS-986094Bristol-Myers SquibbFinancialLegalNovartisPharmaceuticalRare diseasesRegulationRuviseTropical diseases

New executive director of the Global Fund outlines ambitious agenda


Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis…

Anti-viralsAntibiotics and Infectious diseasesFinancialManagementPharmaceuticalTropical diseases

New Zealand to fund Gilead's Atripla and Truvada


New Zealand's Pharmaceutical Management Agency PHARMAC says that, effective December 1, it will fund…

Anti-viralsAsia-PacificAtriplaBiotechnologyFinancialGilead SciencesPharmaceuticalRegulationTruvada

Gilead beats forecasts, posting 14% rise in third-quarter 2012 sales


US antiviral drugs giant Gilead Sciences (Nasdaq: GILD) reported results for the third quarter of 2012,…

Anti-viralsBiotechnologyFinancialGilead Sciences

Arrowhead Research Corp improving focus, say Edison analysts


Last year's acquisition of Roche's RNAi (RNA interference) business (The Pharma Letter October 25, 2011)…

AdipotideAnti-viralsArrowhead ResearchBiotechnologyFinancialMetabolicsOncologyResearch

1 to 25 of 38 results

Back to top